GSK plc Profile Avatar - Palmy Investing

GSK plc

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United …
Drug Manufacturers - General
GB, Brentford [HQ]

Ratios

15 Sheets · Starting from 2023
Margins, Growth Rates In %
Ratio 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Profitability
Gross Margin
73.98 73.26 73.23 70.13 67.61 68.17 62.99 66.69 65.74 66.77 64.85 65.68 65.99 67.42 70.07
Profit Margin
19.50 5.76 19.21 17.27 20.51 11.98 35.20 3.27 5.08 11.75 13.76 16.86 12.85 16.78 16.25
Operating Margin
29.70 13.32 28.51 27.97 26.52 15.64 43.15 9.32 13.54 17.79 20.62 22.82 18.18 21.94 23.06
EPS Growth
22.52 -70.59 227.50 -12.21 22.61 -48.94 202.78 -88.99 62.50 135.90 27.17 23.08 -4.86 -10.95 - -
Return on Assets (ROA)
12.90 3.89 12.81 11.01 12.92 6.78 15.76 1.54 2.72 6.24 5.83 7.15 5.54 8.18 8.35
Return on Equity (ROE)
55.28 18.39 65.50 78.57 77.69 64.65 164.69 81.14 -2,252.94 83.10 38.76 39.41 29.13 46.43 36.92
Return on Invested Capital (ROIC)
23.05 9.26 24.14 21.73 23.57 14.89 37.75 7.15 14.77 15.19 13.87 17.10 14.80 17.81 20.19
Solvency
Equity Ratio
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Debt/Assets
37.93 35.91 36.27 44.13 43.35 46.21 31.12 31.80 30.31 44.89 38.28 33.76 30.56 34.89 28.76
Debt/Equity
162.49 169.91 185.52 315.01 260.76 440.63 325.23 1,671.71 -25,130.88 597.80 254.57 186.13 160.57 198.03 127.12
Debt/EBITDA
99.45 151.47 95.81 164.45 148.72 252.51 87.81 306.28 185.50 301.58 254.72 245.85 226.49 196.07 162.40
Debt/Capitalization
61.90 62.95 64.98 75.90 72.28 81.50 76.48 94.36 100.40 85.67 71.80 65.05 61.62 66.45 55.97
Interest Debt per Share GBP
4.20 3.92 3.90 4.86 4.92 5.07 4.50 5.02 4.56 6.83 7.94 7.04 7.79 5.43 4.38
Debt Growth
0.43 -7.12 -1.32 22.82 -0.31 2.95 -11.46 12.98 -9.05 52.52 17.05 -11.01 -10.97 -13.18 -14.15
Liquidity
Current Ratio
144.99 127.11 107.71 99.11 111.33 110.40 123.63 87.95 59.87 75.26 81.04 91.42 78.89 91.05 88.49
Quick Ratio
111.45 96.69 81.91 70.38 82.82 78.58 88.48 61.10 38.96 50.91 56.32 64.34 54.46 68.49 62.40
Cash Ratio
54.01 48.01 38.07 30.29 40.46 32.63 43.45 25.77 14.43 17.22 19.57 28.41 18.06 16.32 13.94
Operating Cash Flow Ratio
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Turnover
Inventory Turnover
181.59 197.86 189.31 198.89 220.13 173.08 187.72 182.09 186.11 187.02 199.48 195.20 200.64 185.66 165.08
Receivables Turnover
433.10 485.42 - - 642.31 668.31 646.96 625.60 471.34 507.33 487.52 472.22 469.43 424.78 412.14 409.67
Payables Turnover
108.98 110.22 99.63 98.01 103.22 92.02 96.32 77.65 49.32 72.96 79.41 73.89 66.10 58.75 244.18
Asset Turnover
66.18 67.52 66.67 63.73 62.98 56.59 44.76 47.20 53.54 53.08 42.36 42.40 43.13 48.75 51.40
Coverage
Interest Coverage
1,075.99 455.23 977.10 914.85 916.30 494.77 1,363.54 352.99 556.81 687.09 763.27 872.53 790.94 731.85 902.32
Asset Coverage
100 100 100 100 100 100 100 100 - - - - 100 100 100 100 100
Cash Flow Coverage (CFGR)
48.23 45.01 41.94 23.90 39.58 27.56 15.45 34.58 40.48 32.31 26.29 31.09 32.90 35.27 37.41
EBITDA Coverage
1,200 700 1,200 1,000 1,100 700 1,600 600 900 900 1,100 900 1,100 1,000 1,100
Dividend Coverage
-100 - - -100 -100 -100 - - -200 - - - - - - -100 -100 -100 -100 -200
Time Interest Earned (TIE)
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Market Prospects
Dividend Yield
5.72 6.29 5.70 7.20 5.85 7.19 7.23 7.91 7.48 6.63 5.56 7.37 7.70 5.99 3.82
Earnings Yield
10.23 3.21 8.80 8.62 8.64 5.16 15.71 1.49 2.93 6.12 6.53 10.65 8.44 8.50 8.39
Price/Earnings (P/E)
977.16 3,118.17 1,136.39 1,160.74 1,157.25 1,939.74 636.40 6,726.07 3,408.23 1,634.34 1,530.98 938.59 1,185.12 1,176.14 1,192.41
Price/Book (P/B)
540.20 573.32 744.34 912.01 899.07 1,254.03 1,048.06 5,457.45 -76,785.50 1,358.08 593.41 369.92 345.18 546.12 440.26
Price/Sales (P/S)
190.52 179.46 218.30 200.48 237.34 232.37 224.04 219.95 172.97 192.12 210.68 158.24 152.34 197.37 193.76
Price/Cash Flow (P/CF)
689.29 749.61 956.57 1,211.15 871.06 1,032.83 2,086.33 944.16 754.76 703.15 886.71 639.26 653.52 781.82 925.68
End of GSK's Analysis
CIK: 1131399 CUSIP: 37733W204 ISIN: US37733W2044 LEI: - UEI: -
Secondary Listings